Showing 331-340 of 2936 results for "".
- BeautyHealth Appoints Bluemercury Founder Marla Beck to Board of Directorshttps://modernaesthetics.com/news/beautyhealth-appoints-bluemercury-founder-marla-beck-to-board-of-directors/2473249/Bluemercury founder Marla Beck is now a member ofThe Beauty Health Company’s Board of Directors. As founder and former CEO of Bluemercury, the disruptive omnichannel beauty retailer founded in 1999 and acquired by Macy’s in 2015, Ms. Beck has a track record of building
- Cynosure Rolls Out PicoSure Pro Devicehttps://modernaesthetics.com/news/cynosure-rolls-out-picosure-pro-device/2473248/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. The FDA-cleared 755nm picosecond laser on the market, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide
- Dr. Paul M. Friedman Named New ASLMS Presidenthttps://modernaesthetics.com/news/dr-paul-m-friedman-named-new-aslms-president/2473244/Paul M. Friedman, MD is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Friedman, board-certified by the American Board of Dermatology, is the director of Dermatology & Laser Surgery Center of Houston
- CoolSculpting's New DTC Campaign is Brand's First to Feature Real Experiences with Treatmenthttps://modernaesthetics.com/news/coolsculptings-new-dtc-campaign-is-brands-first-to-feature-real-experiences-with-treatment/2473238/The newest direct-to-consumer campaign from CoolSculpting® launches this month and marks the first time the brand is featuring the real experiences of real people who have been treated with CoolSculpting® and CoolTone®. “CoolSculpting® Takes You Further&rdquo
- Cynosure Receives $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://modernaesthetics.com/news/cynosure-recieves-60-million-follow-on-investment-from-clayton-dubilier-rice/2473237/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its cust
- ISHRS Survey: Surgical Advances; Improvements in Efficiency Driving Need for Fewer Hair Transplant Treatmentshttps://modernaesthetics.com/news/ishrs-survey-surgical-advances-improvements-in-efficiency-driving-need-for-fewer-hair-transplant-treatments/2473235/According to results of a new member survey conducted by the International Society of Hair Restoration Surgery (ISHRS), 68 percent of members reported performing an average of one procedure per patient in 2021 to achieve the desired hair restoration result. This represents a significant improveme
- CellFX from Pulse Biosciences Shows Durable Effects for Sebaceous Hyperplasia: ASLMS Presentationhttps://modernaesthetics.com/news/cellfx-from-pulse-biosciences-shows-durable-effects-for-sebaceous-hyperplasia-aslms-presentation/2473233/The CellFX® system from Pulse Biosciences, Inc. demonstrates durable efficacy for the clearance of Sebaceous Hyperplasia lesions, according to data presented at the 2022
- R2 Technologies Ships 100 GLACIAL Deviceshttps://modernaesthetics.com/news/r2-technologies-ships-100-glacial-devices/2473224/R2 Technologies Inc. has shipped 100 GLACIAL Rx devices across the globe. To-date customers have delivered more than 15,000 GLACIAL treatment cycles, helping patients reach their skin goals by reducing inflammation and revealing younger looking skin. R2 reached this mileston
- Revance News: FDA Accepts BLA Resubmission for DaxibotulinumtoxinAhttps://modernaesthetics.com/news/revance-news-fda-accepts-bla-resubmission-for-daxibotulinumtoxina/2473223/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont
- Jeune Aesthetics Shares Positive Clinical Phase 1 Data for Investigational Gene-based Treatment to Address the Underlying Biology of Aging Skinhttps://modernaesthetics.com/news/jeune-aesthetics-shares-positive-clinical-phase-1-data-for-investigational-gene-based-treatment-to-address-the-underlying-biology-of-aging-skin/2473210/Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc. shared positive proof-of-concept efficacy data from Cohort 2 of its PEARL-1 study of KB301, Jeune Aesthetics’ lead candidate for the treatment of aesthetic skin conditions. “We are pleased to see